Advancing Your Clinical Capabilities

The demands placed on laboratories today aren’t just growing – they’re also evolving. More complex diseases, combined with a broader range of conditions and patient populations, mean laboratorians need to constantly advance their research and clinical capabilities to help clinicians best meet their patients’ needs. But they can’t do it alone.

At Beckman Coulter Diagnostics, we are with you — today and tomorrow. Our teams are constantly innovating for the future, focusing our efforts on advancing your clinical capabilities with diagnostics that are accurate, sensitive, timely, accessible, and less invasive.

How do we do it? We asked members of our Medical and Scientific Affairs team for real-world examples of how our solutions are helping advance clinical capabilities every day, all around the world.

Clinical Confidence
More complex conditions require more complex decision-making. That’s why we are constantly innovating new additions, enhancements, and expansions to our test menu.

“When a hospital or health system invests in new technology for its labs, it’s a long-term decision. They need to be confident that those instruments and assays will continuously evolve to address the latest conditions and challenges,” says Lindsay Sun, Medical Director at Beckman Coulter. “That’s why innovation is a core component of who we are.”

“One recent example of innovation lies in the growing field of neurodegenerative testing for conditions like Alzheimer’s Disease.” says Sun. “Beckman Coulter’s p-Tau217/ß-AmyIoid 1-42 Plasma Ratio assay recently received Breakthrough Device Designation from the FDA.* Our pTau217/Aβ42 ratio shows enhanced performance in identifying amyloid (Aβ+) pathology compared to individual biomarkers and may help reduce uncertainty in research classifications. These findings support the potential utility of plasma biomarker ratios as investigational tools for early-stage Alzheimer's disease research and biomarker development.”

“The recent FDA approval of another pTau217/Aβ42 ratio blood test marks a watershed moment in Alzheimer’s care and opens the door to a new era of diagnosis and treatment. This advancement arrives alongside the recent approvals of disease-modifying therapies, offering new hope to millions affected by the disease.”

Improved Efficiency
The need for efficiency in the lab is nothing new. Reducing turnaround times and repeat testing have long been benefits of our analyzers and assays—but Dr. Tobin Efferen, Beckman Coulter Medical Director and practicing Emergency Physician, reminds us why we continue striving every day to do even better.

“Improved efficiency isn’t just a lab benefit,” Dr. Efferen points out. “It’s a patient benefit. It’s a physician benefit. It’s even a surgical benefit. For example, our DxI 9000 analyzer with our Parathyroid Hormone assay can deliver accurate ioPTH results in as little as eight minutes. Our ability to run this test so quickly does more than help the lab run smoothly; it gives surgical teams confidence in the outcomes of their procedures even before the procedure is complete. I love hearing how the impact of diagnostics reaches into critical areas of healthcare like this.”

Collaborative Intelligence
Reimagining diagnostics takes all of us, so we are partnering with other innovators to go farther together. 

Medical Director Kinal Bhatt, a member of Beckman Coulter’s Medical and Scientific Affairs team with a focus on Neurology, mentions some of the key partnerships Beckman Coulter is currently engaged in. She says, “We are proud to work with other academic and industry leaders to innovate new solutions. We’re working with companies like Biogen and Fujirebio to revolutionize the future of Alzheimer’s disease testing. We’ve partnered with MeMed to help physicians distinguish between bacterial and viral infections for better-informed care decisions. Our collaboration with Scopio Labs is helping us deliver more insights from a single blood draw than ever before. We’re reaching well beyond our roots to extend our expertise into new areas that can have the greatest impact today.”

Innovating For Clinical Capabilities. Innovating For Care.
With greater confidence, improved efficiency, and collaborative intelligence, you can deliver the specialized care your patients need today—and prepare for the care they may need tomorrow. Dive deeper into how we’re helping advance your clinical capabilities, then talk to your Beckman Coulter representative to learn more.